Stockhub

X4 Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

31 July 2022

  • curprev 20:0820:08, 31 July 2022‎ Chris talk contribs‎ 1,040 bytes +1,040‎ Created page with "X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/X4_Pharmaceuticals,_Inc.’